Cutaneous Oncology

Melanoma

Resectable
Stage II

None at this Time

MEL0036
Phase III
Multi-Centre
Multi-National
Randomised
Control Trial
Investigating 1cm
v 2cm Wide
Excision Margins in Primary
Cutaneous
Melanoma

PI: Kirane
Sponsor: Melanoma and Skin Cancer Trials
Limited (MASC Trials)

Resectable
Stage III-IV

None at this Time

MEL0033
Phase III, Randomized,
Open-label, Study of
Subcutaneous Nivolumab + Relatlimab Fixed-dose
Combination vs Intravenous Nivolumab + Relatlimab Fixed-dose
Combination in Previously Untreated Metastatic or Unresectable Melanoma

PI: Reddy
Sponsor: Bristol-Myers Squibb

Unresectable
Stage III-IV

Not Eligible for TILs

MEL0033
Phase III, Randomized,
Open-label, Study of
Subcutaneous Nivolumab + Relatlimab Fixed-dose
Combination vs Intravenous Nivolumab + Relatlimab Fixed-dose
Combination inPreviously Untreated Metastatic or Unresectable Melanoma

PI: Reddy
Sponsor: Bristol-Myers Squibb

Eligible for TILs

Stage IIIC, IIID, or IV Unresectable or Metastatic Melanoma

VAR0241
Phase III
Open-Label Study of PD-1 Knockout Tumor-Infiltrating Lymphocytes (iov-4001) in Unresectable or Metastatic Melanoma or Stage III or IV Non-Small-Cell Lung Cancer

PI: Betof
Sponsor: Iovance Biotherapeutics, Inc.

KEY

- Pending
- Open for Enrollment
- Link
- Optional Path
- Trial Posting
- Extension Study
- Immunotherapy
- Enrollment on Hold

Please mark up a copy using black ink and email changes to SRC-office@stanford.edu